A Novel Camel Milk-Derived Peptide LLPK Improves Glucose-Lipid Metabolism in <i>db</i>/<i>db</i> Mice via PPAR Signaling Pathway.

ABSTRACT: Background: Camel milk is considered to be an important source of bioactive peptides with potential anti-diabetic effects. However, the mechanism by which these active peptides exert their anti-diabetic effects is not clear. The aim of this study was to systematically evaluate the in vivo anti-diabetic effects of Leucine-Leucine-Proline-Lysine (LLPK), a novel dipeptidyl peptidase-4 (DPP-4) inhibitory peptide identified from the in vitro gastrointestinal digestion product of camel milk. Methods: A db/db diabetic mouse model was used, and LLPK was administered to mice at doses of 50 mg/kg BW and 100 mg/kg BW as a daily oral gavage for 30 days. The effects of LLPK on fasting blood glucose (FBG), oral glucose tolerance test (OGTT), insulin tolerance test (ITT), and

SUBMITTER: Han B 

PROVIDER: S-EPMC12113985 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature